Successful treatment of fulminant neonatal enteroviral myocarditis in monochorionic diamniotic twins with cardiopulmonary support, intravenous immunoglobulin and pocapavir

BMJ Case Rep. 2018 May 18:2018:bcr2017224133. doi: 10.1136/bcr-2017-224133.

Abstract

Neonatal cardiogenic shock most commonly occurs due to critical congenital heart disease, sepsis, metabolic disorder or arrhythmias. In particular, enterovirus infections are common in the neonatal period, and patients can present with fulminant myocarditis. Early recognition is imperative due to its high morbidity and mortality without prompt and aggressive treatment. We present the successful treatment of fulminant neonatal enteroviral myocarditis in a pair of monochorionic diamniotic twins with cardiopulmonary support, intravenous immunoglobulin and pocapavir, an enteroviral capsid inhibitor. The twins took an almost exact parallel hospital course, including day of extracorporeal membrane oxygenation (ECMO) cannulation, day of ECMO decannulation, improvement of cardiac function, discharge and status at follow-up. While it was difficult to assess the relative contribution of each intervention, our case shows promise in the use of pocapavir for treatment of severe enteroviral infections. Remarkably, both twins demonstrated remarkable recovery within 2 weeks, underscoring that early aggressive cardiopulmonary support, and potentially pocapavir, contributed to their recovery.

Keywords: cardiovascular system; heart failure; infections; paediatric intensive care.

Publication types

  • Case Reports

MeSH terms

  • Antiviral Agents / therapeutic use*
  • Combined Modality Therapy
  • Diseases in Twins / therapy*
  • Diseases in Twins / virology
  • Enterovirus Infections / complications
  • Enterovirus Infections / therapy*
  • Extracorporeal Membrane Oxygenation / methods*
  • Heart / virology
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use*
  • Infant, Newborn
  • Male
  • Myocarditis / therapy*
  • Myocarditis / virology
  • Phenyl Ethers / therapeutic use*
  • Shock, Cardiogenic / therapy*
  • Shock, Cardiogenic / virology
  • Treatment Outcome
  • Twins, Monozygotic

Substances

  • Antiviral Agents
  • Immunoglobulins, Intravenous
  • Phenyl Ethers
  • pocapavir